Literature DB >> 20597189

Placebo effects in treating migraine and other headaches.

Hans-Christoph Diener.   

Abstract

Evaluating the efficacy of a drug therapy in the acute and prophylactic treatment of migraine requires the conduct of placebo-controlled, randomized clinical trials. In order to plan and conduct these studies in the most appropriate manner, it is desirable to know which factors influence the placebo response. This editorial overview discusses the factors that influence placebo response in trials for migraine and other headaches; such factors include expectation, blinding, route of drug administration, patient age and gender, and geographic distribution of the trials. The placebo response rates in the treatment of acute headache episodes are higher than in headache prophylaxis, and invasive procedures, such as injections, have a higher placebo response compared with orally administered drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20597189

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

1.  Melatonin for migraine prevention.

Authors:  Mario Fernando Prieto Peres
Journal:  Curr Pain Headache Rep       Date:  2011-10

2.  A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Authors:  Roger K Cady; Peter J McAllister; Egilius L H Spierings; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2014-10-30       Impact factor: 5.887

Review 3.  Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials.

Authors:  Nada A Hindiyeh; Donald J Kellerman; Peter C Schmidt
Journal:  Headache       Date:  2019-04-06       Impact factor: 5.887

4.  Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.

Authors:  Pepa Polavieja; Mark Belger; Shiva Kumar Venkata; Stefan Wilhelm; Erin Johansson
Journal:  J Headache Pain       Date:  2022-07-06       Impact factor: 8.588

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.